Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100(13):4325–4336

Article  CAS  PubMed  Google Scholar 

Mrózek K, Heerema NA, Bloomfield CD (2004) Cytogenetics in acute leukemia. Blood Rev 18(2):115–136

Article  PubMed  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345–1377

Article  PubMed  Google Scholar 

Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL et al (2015) Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125(9):1367–1376

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L et al (2008) Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. N Engl J Med 358(18):1909–1918

Article  CAS  PubMed  Google Scholar 

Sharma R, Jamwal M, Singh N, Sharma P, Bansal D, Trehan A et al (2023) Genetic spectrum in F13A1 detected by next-generation sequencing among north indian patients with FXIII deficiency. Indian J Hematol Blood Transfus 39(2):276–283

Article  PubMed  Google Scholar 

Waterhouse K, Katta A, Teckman J, Foy T, Derdoy J, Jain A et al (2011) Vitamin D levels in children with eosinophilic esophagitis and gastroesophageal reflux. J Allergy Clin Immunol 127(2):AB107

Article  Google Scholar 

Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL et al (2021) 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood 138(26):2753–2767

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan O, Al Ali N, Tashkandi H, Ellis A, Ball S, Grenet J et al (2024) Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv 8(5):1075–1083

Article  CAS  PubMed  PubMed Central  Google Scholar 

DiNardo Courtney D, Jonas Brian A, Pullarkat V, Thirman Michael J, Garcia Jacqueline S, Wei Andrew H et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383(7):617–629

Article  CAS  PubMed  Google Scholar 

Shimony S, Garcia JS, Keating J, Chen EC, Luskin MR, Stahl M et al (2024) Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. Leukemia

Wang E, Pineda JMB, Kim WJ, Chen S, Bourcier J, Stahl M et al (2023) Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia. Cancer Cell 41(1):164–80e8

Article  CAS  PubMed  Google Scholar 

Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM et al (2022) Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. Am J Hematol 97(6):E214–E6

Article  CAS  PubMed  Google Scholar 

Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG et al (2024) Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax. Blood Adv 8(4):927–935

Article  CAS  PubMed  Google Scholar 

Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M et al (2024) Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol 99(2):193–202

Article  CAS  PubMed  Google Scholar 

Döhner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL et al (2024) Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 144(21):2169–2173

Article  PubMed  Google Scholar